AJP - Renal AJP: Regulatory, Integrative and Comparative Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 258: F1504-F1509, 1990;
0363-6127/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Handa, R. K.
Right arrow Articles by Buckalew, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Handa, R. K.
Right arrow Articles by Buckalew, V. M., Jr

AJP - Renal Physiology, Vol 258, Issue 6 1504-F1509, Copyright © 1990 by American Physiological Society

ARTICLES

Platelet-activating factor is a renal vasodilator in the anesthetized rat

R. K. Handa, J. W. Strandhoy and V. M. Buckalew Jr
Department of Medicine/Nephrology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.

In view of the potent vasoactive properties of platelet-activating factor (PAF), we investigated the renal hemodynamic effects of this lipid. C16-PAF (0.5-10 ng/kg) given as a bolus into the renal arterial circulation of pentobarbital sodium-anesthetized male Wistar rats produced a dose-dependent increase in renal blood flow (6-15%), before causing systemic hypotension. The PAF-induced renal vasodilation and systemic hypotension was independent of renal innervation, unaltered by eicosanoid synthesis inhibition with indomethacin or dexamethasone, unchanged by the nonselective dopamine-receptor antagonist haloperidol, but was abolished by the PAF-receptor antagonist, L-659,989. Non-hypotensive intrarenal PAF infusion at 0.5 ng.min-1.kg-1 caused an increase in renal blood flow. Thus PAF can cause renal vasodilation in the rat kidney that is PAF-receptor mediated and does not involve the sympathetic nervous system or the release of vasodilatory arachidonic acid metabolites or dopamine.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
R. K. Handa, J. W. Strandhoy, C. E. Giammattei, and S. E. Handa
Platelet-activating factor and solute transport processes in the kidney
Am J Physiol Renal Physiol, February 1, 2003; 284(2): F274 - F281.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
G. Montrucchio, G. Alloatti, and G. Camussi
Role of Platelet-Activating Factor in Cardiovascular Pathophysiology
Physiol Rev, October 1, 2000; 80(4): 1669 - 1699.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. G. Greenberg and K. E. Clark
Hemodynamic effects of platelet-activating factor in nonpregnant and pregnant sheep
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1999; 277(4): R996 - R1001.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online